Prolonged tumor necrosis factor α primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin

Arthritis and Rheumatology

Volumn 67, Issue 1, 2015, Pages 86-95

  Sohn, Christopher ^a   Lee, Angela ^a   Qiao, Yu ^a   Loupasakis, Konstantinos ^a   Ivashkiv, Lionel B ^b   Kalliolias, George D ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Weill Cornell Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; I KAPPA B; RNA POLYMERASE II; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CHROMATIN; HISTONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ARTICLE; CHROMATIN; CHROMATIN IMMUNOPRECIPITATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; FIBROBLAST LIKE SYNOVIOCYTE; GENE AMPLIFICATION; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOPRECIPITATION; LONG TERM EXPOSURE; PATHOGENESIS; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; TOTAL KNEE REPLACEMENT; WESTERN BLOTTING; CELL CULTURE; DRUG EFFECTS; METABOLISM; PATHOLOGY; SYNOVIUM; TIME;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; CHEMOKINE CXCL10; CHEMOKINE CXCL11; CHEMOKINE CXCL9; CHROMATIN; FIBROBLASTS; HISTONES; HUMANS; NF-KAPPA B; RNA POLYMERASE II; STAT1 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919940967     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38871     Document Type: Article

References (49)

1. Klareskog L, Malmstrom V, Lundberg K, Padyukov L, Alfredsson L,. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol 2011; 23: 92-8.
2. Brusca SB, Abramson SB, Scher JU,. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheumatol 2014; 26: 101-7.
3. Viatte S, Plant D, Raychaudhuri S,. Genetics and epigenetics of rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 141-53.
4. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H, et al. Systematic localization of common disease-associated variation in regulatory DNA. Science 2012; 337: 1190-5.
5. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P,. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-74.
6. Chakravarty SD, Poulikakos PI, Ivashkiv LB, Salmon JE, Kalliolias GD,. Kinase inhibitors: a new tool for the treatment of rheumatoid arthritis. Clin Immunol 2013; 148: 66-78.
7. Prince FH, Bykerk VP, Shadick NA, Lu B, Cui J, Frits M, et al. Sustained rheumatoid arthritis remission is uncommon in clinical practice. Arthritis Res Ther 2012; 14: R68.
8. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, et al. Cadherin-11 in synovial lining formation and pathology in arthritis. Science 2007; 315: 1006-10.
9. Bottini N, Firestein GS,. Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 2012; 9: 24-33.
10. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, et al. Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. Am J Pathol 1996; 149: 1607-15.
11. Noss EH, Brenner MB,. The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. Immunol Rev 2008; 223: 252-70.
12. Buckley CD,. Why does chronic inflammation persist: an unexpected role for fibroblasts. Immunol Lett 2011; 138: 12-4.
13. Kawane K, Ohtani M, Miwa K, Kizawa T, Kanbara Y, Yoshioka Y, et al. Chronic polyarthritis caused by mammalian DNA that escapes from degradation in macrophages. Nature 2006; 443: 998-1002.
14. Kawane K, Tanaka H, Kitahara Y, Shimaoka S, Nagata S,. Cytokine-dependent but acquired immunity-independent arthritis caused by DNA escaped from degradation. Proc Natl Acad Sci U S A 2010; 107: 19432-7.
15. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31.
16. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G,. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999; 10: 387-98.
17. Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G,. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008; 205: 331-7.
18. Lee A, Qiao Y, Grigoriev G, Chen J, Park-Min KH, Park SH, et al. Tumor necrosis factor α induces sustained signaling and a prolonged and unremitting inflammatory response in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum 2013; 65: 928-38.
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
20. Ohmori Y, Hamilton TA,. The interferon-stimulated response element and a κB site mediate synergistic induction of murine IP-10 gene transcription by IFN-γ and TNF-α. J Immunol 1995; 154: 5235-44.
21. Imaizumi T, Matsumiya T, Yoshida H, Naraoka T, Uesato R, Ishibashi Y, et al. Tumor-necrosis factor-α induces retinoic acid-inducible gene-I in rheumatoid fibroblast-like synoviocytes. Immunol Lett 2009; 122: 89-93.
22. Rosengren S, Corr M, Firestein GS, Boyle DL,. The JAK inhibitor CP-690,550 (tofacitinib) inhibits TNF-induced chemokine expression in fibroblast-like synoviocytes: autocrine role of type I interferon. Ann Rheum Dis 2012; 71: 440-7.
23. Firestein GS, Alvaro-Gracia JM, Maki R,. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347-53.
24. Sengupta TK, Chen A, Zhong Z, Darnell JE Jr, Ivashkiv LB,. Activation of monocyte effector genes and STAT family transcription factors by inflammatory synovial fluid is independent of interferon γ. J Exp Med 1995; 181: 1015-25.
25. Tak PP,. IFN-β in rheumatoid arthritis. Front Biosci 2004; 9: 3242-7.
26. Kalliolias GD, Ivashkiv LB,. Overview of the biology of type I interferons. Arthritis Res Ther 2010; 12 Suppl 1: S1.
27. Hu X, Ivashkiv LB,. Cross-regulation of signaling pathways by interferon-γ: implications for immune responses and autoimmune diseases. Immunity 2009; 31: 539-50.
28. Ohmori Y, Schreiber RD, Hamilton TA,. Synergy between interferon-γ and tumor necrosis factor-γ in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB. J Biol Chem 1997; 272: 14899-907.
29. Saccani S, Pantano S, Natoli G,. p38-Dependent marking of inflammatory genes for increased NF-κB recruitment. Nat Immunol 2002; 3: 69-75.
30. Natoli G,. NF-κB and chromatin: ten years on the path from basic mechanisms to candidate drugs. Immunol Rev 2012; 246: 183-92.
31. Fransen L, Van der Heyden J, Ruysschaert R, Fiers W,. Recombinant tumor necrosis factor: its effect and its synergism with interferon-γ on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 1986; 22: 419-26.
32. Wong GH, Goeddel DV,. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature 1986; 323: 819-22.
33. Bartee E, Mohamed MR, McFadden G,. Tumor necrosis factor and interferon: cytokines in harmony. Curr Opin Microbiol 2008; 11: 378-83.
34. Qiao Y, Giannopoulou EG, Chan CH, Park SH, Gong S, Chen J, et al. Synergistic activation of inflammatory cytokine genes by interferon-γ-induced chromatin remodeling and Toll-like receptor signaling. Immunity 2013; 39: 454-69.
35. Yarilina A, Park-Min KH, Antoniv T, Hu X, Ivashkiv LB,. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 2008; 9: 378-87.
36. Gordon RA, Grigoriev G, Lee A, Kalliolias GD, Ivashkiv LB,. The interferon signature and STAT1 expression in rheumatoid arthritis synovial fluid macrophages are induced by tumor necrosis factor α and counter-regulated by the synovial fluid microenvironment. Arthritis Rheum 2012; 64: 3119-28.
37. Hu X, Herrero C, Li WP, Antoniv TT, Falck-Pedersen E, Koch AE, et al. Sensitization of IFN-γ Jak-STAT signaling during macrophage activation. Nat Immunol 2002; 3: 859-66.
38. Monticelli S, Natoli G,. Short-term memory of danger signals and environmental stimuli in immune cells. Nat Immunol 2013; 14: 777-84.
39. Genovese MC, Chakravarty EF, Krishnan E, Moreland LW,. A randomized, controlled trial of interferon-β1a (Avonex®) in patients with rheumatoid arthritis: a pilot study [ISRCTN03626626]. Arthritis Res Ther 2004; 6: R73-7.
40. Veys EM, Menkes CJ, Emery P,. A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-γ versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997; 40: 62-8.
41. Kuan WP, Tam LS, Wong CK, Ko FW, Li T, Zhu T, et al. CXCL 9 and CXCL 10 as sensitive markers of disease activity in patients with rheumatoid arthritis. J Rheumatol 2010; 37: 257-64.
42. Hanaoka R, Kasama T, Muramatsu M, Yajima N, Shiozawa F, Miwa Y, et al. A novel mechanism for the regulation of IFN-γ inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003; 5: R74-81.
43. Lee EY, Lee ZH, Song YW,. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis. Autoimmun Rev 2012; 12: 554-7.
44. Zernecke A, Shagdarsuren E, Weber C,. Chemokines in atherosclerosis: an update. Arterioscler Thromb Vasc Biol 2008; 28: 1897-908.
45. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N,. Targeting the function of IFN-γ-inducible protein 10 suppresses ongoing adjuvant arthritis. J Immunol 2002; 169: 2685-93.
46. Mohan K, Issekutz TB,. Blockade of chemokine receptor CXCR3 inhibits T cell recruitment to inflamed joints and decreases the severity of adjuvant arthritis. J Immunol 2007; 179: 8463-9.
47. Kwak HB, Ha H, Kim HN, Lee JH, Kim HS, Lee S, et al. Reciprocal cross-talk between RANKL and interferon-γ-inducible protein 10 is responsible for bone-erosive experimental arthritis. Arthritis Rheum 2008; 58: 1332-42.
48. O'Boyle G, Fox CR, Walden HR, Willet JD, Mavin ER, Hine DW, et al. Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation. Proc Natl Acad Sci U S A 2012; 109: 4598-603.
49. Yellin M, Paliienko I, Balanescu A, Ter-Vartanian S, Tseluyko V, Xu LA, et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 1730-9.